@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVs6b9
@ASCO
#SocialListening #LucidQuest
@scienceinboston.com🩸A blood test for #ctDNA may help doctors identify which patients with #EwingSarcoma are at greater risk of relapse.
Learn more about the study from Drs. David Shulman, Brian Crompton, and Steven DuBois at @danafarber.bsky.social: https://bit.ly/4xW09aL
@yalecancer.bsky.socialThank you Dr. David Cescon of Princess Margaret Cancer Centre for presenting our #GrandRounds / Kingsbury Lecture in Breast Cancer, sharing insights on emerging data on #ctDNA monitoring in metastatic #breastcancer.
➡️Watch his full talk: youtube.com/watch?v=CyRc...
@newsen.bsky.socialHaystack MRD® Test Achieves Outstanding Results in DYNAMIC Colorectal Cancer Trials #United_States #Secaucus #Colorectal_Cancer #ctDNA #Haystack_MRD
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVk8mN
@ASCO
#SocialListening #LucidQuest
@jco-asco.bsky.socialCan early #ctDNA kinetics tell us more than PSA alone in #mCRPC?
This review examines ctDNA across ARPIs, chemotherapy, PARP inhibitors & PSMA-targeted radioligand therapy.
Read about the findings. https://bit.ly/4hepzeK
#ProstateCancer #LiquidBiopsy
@mamjournal.bsky.social🧬 What does a ctDNA result really mean?
A new review by Garcia et al. highlights a key point in liquid biopsy: circulating tumor DNA is shaped by a dynamic balance between tumor shedding and clearance.
📄 Garcia et al., Molecular Aspects of Medicine, 2026.
#ctDNA #LiquidBiopsy #CancerResearch
@duboisrn.bsky.social#ctDNA Assay Shows High Specificity for Post-Transplant #LiverCancer Recurrence: www.cancernetwork.com/view/ctdna-a...
@crukconvergence.bsky.social🔬Dr @Stefan Antonowicz (@imperialcollegeldn.bsky.social) on metabolic variation in oesophageal adenocarcinoma
🔬Dr Izzie Cartwright (@royalmarsden.org) on #ctDNA and GI cancer
📅1 October, 10–11am
🔗 lnkd.in/eqTc-3kN
@sinclaircri.bsky.socialToday at 3PM: seminar with @dyrskjot.bsky.social (Aarhus Univ), hosted by our CBG division's Dr. Madhuri Koti @sinclaircri.bsky.social. Drop in — everyone welcome. Info/questions: [email protected] #BladderCancer #ctDNA #CancerResearch
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVZrrx
@ASCO
#SocialListening #LucidQuest
@rcatanho.bsky.socialDNA tumoral circulante es pronóstico en el sarcoma de Ewing, diferenciando a los grupos que integran el DNA tumoral con rasgos clínicos moleculares según el riesgo #ewing #ctDNA ascopubs.org/doi/full/10....
@darwishmd.bsky.socialBlood tests for tumor DNA (ctDNA) can spot leftover cancer months before scans do, and help doctors pick targeted drugs. New JAMA review: promising, but costs and best-use timing are still being worked out.
@knstnr.bsky.social🧬 New paper! Within #InstandNGS4P we developed MRD prototypes detecting ctDNA in blood plasma to support diagnosis of pancreatic & ovarian cancer — UMI-based error correction + ultra-deep sequencing.
📄 Open Research Europe: open-research-europe.ec.europa.eu/articles/6-87
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVRwF2
@ASCO
#SocialListening #LucidQuest
@mdpm2026.bsky.socialAdvances in Molecular Diagnostics and Precision Medicine 2027
📅 June 17–18, 2027
📍 Zurich, Switzerland
Registration: advancedmoleculardx.com/registrations/
#MDPM2027 #LiquidBiopsy #MolecularDiagnostics #PrecisionMedicine #ctDNA #CancerDiagnostics #Genomics #PersonalizedMedicine #SciinovGroup
@drjkyl.bsky.socialClinical Utility of Circulating Tumor DNA Analysis in Pancreatic Ductal Adenocarcinoma
Clinical Medicine Insights: Oncology
@journals.sagepub.com
@jco-asco.bsky.socialCould #ctDNA provide an early window into treatment response in #BreastCancer?
In a prospective pilot study, ctDNA clearance within 6 weeks was associated with lower postsurgical tumor burden and ctDNA positivity.
Read the article. https://bit.ly/3SBrMau
@jco-asco.bsky.socialAcross 162 studies, early on-treatment #ctDNA reductions were associated with improved overall survival across advanced solid tumors and treatments.
Findings support ctDNA dynamics as a potential early trial endpoint, but standardization is essential.
Read the article. https://bit.ly/4cXXq8Y
@jamaotolaryngology.comFor #HeadAndNeckSquamousCellCarcinoma surveillance, tissue-informed #ctDNA positivity was sometimes the first sign of recurrence and showed high positive and negative predictive value.
